Advanced search
Publication Cover
Journal of Medical Economics Volume 23, 2020 - Issue 6
Submit an article Journal homepage
1,305
Views
0
CrossRef citations to date
0
Altmetric
Cardiovascular Medicine

Cost-effective analysis of clopidogrel versus aspirin for high risk patients with established peripheral arterial disease in China

Ziyi LinHealth Economics Department, Shanghai Centennial Scientific, Shanghai, China;
,
Lei ZhangHealth Economics Department, Shanghai Centennial Scientific, Shanghai, China;
,
Xiaoyan YangHealth Economics and Outcome Research, Sanofi, Shanghai, China;
,
Li LiuHealth Economics and Outcome Research, Sanofi, Shanghai, China;
&
Jianwei XuanHealth Economics Research Institute, Sun Yat-sen University, Guangzhou, ChinaCorrespondence[email protected]
Pages 659-666 | Received 18 Dec 2019, Accepted 20 Jan 2020, Published online: 24 Feb 2020

References

  • Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. J Am Med Assoc. 2001;286(11):1317–1324.
  • Bhatt DL, Gabriel Steg P, Magnus Ohman E, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. J Am Med Assoc. 2006;295(2):180–189.
  • Diehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120(21):2053–2061.
  • Fowkes G, Fowkes FGR, Murray GD, et al. Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis. J Am Med Assoc. 2008;300(2):197–208.
  • Allison MA, Ho E, Denenberg JO, et al. Ethnic-specific prevalence of peripheral arterial disease in the United States. Am J Prev Med. 2007;32(4):328–333.
  • Sebastianski M, Makowsky MJ, Dorgan M, et al. Paradoxically lower prevalence of peripheral arterial disease in South Asians: a systematic review and meta-analysis. Heart. 2014;100(2):100–105.
  • Wang Y, Li J, Xu Y, et al. Prevalence of peripheral arterial disease and correlative risk factors among natural population in China. Zhonghua Xin Xue Guan Bing Za Zhi. 2009;37(12):127–131.
  • Li H, Ge J. Cardiovascular diseases in China: current status and future perspectives. Int J Cardiol Heart Vasc. 2015;6:25–31.
  • CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (London, England). 1996;348:1329–1339.
  • Ringleb PA, Bhatt DL, Hirsch AT, et al. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke. 2004;35(2):528–532.
  • Logman JFS, Heeg BMS, Herlitz J, et al. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (High-Risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations. Appl Health Econ Health Policy. 2010;8(4):251–265.
  • Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Expert consensus of antiplatelet therapy in cardiovascular disease. Zhonghua Xin Xue Guan Bing Za Zhi. 2013;41:183–194.
  • Olsen J, Heeg B, Van Gestel A, et al. Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark. Ugeskr Laeger. 2006;168(35):2911–2915.
  • Heeg BMS, Peters RJG, Botteman M, et al. Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention. Pharmacoeconomics. 2007;25(9):769–782.
  • Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival-for cost-effectiveness analyses: a case study in atherothrombosis. Value Health. 2004;7(5):627–635.
  • Zhang L, Lin Z, Yin H, et al. Clopidogrel versus aspirin for the treatment of acute coronary syndrome after a 12-month dual antiplatelet therapy: a cost-effectiveness analysis from China payer ‘s perspective. Clin Ther. 2018;40(12):2125–2137.
  • Cui M, Tu CC, Chen EZ, et al. A cost-effectiveness analysis of clopidogrel for patients with non-ST-segment elevation acute coronary syndrome in China. Adv Ther. 2016;33(9):1600–1611.
  • Berger K, Hessel F, Kreuzer J, et al. Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. Curr Med Res Opin. 2008;24(1):267–274.
  • Kourlaba G, Fragoulakis V, Maniadakis N. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece. Appl Health Econ Health Policy. 2012;10(5):331–342.
  • Annemans L, Lamotte M, Levy E, et al. Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial. J Med Econ. 2003;6(1–4):55–68.
  • Li T, Liu M, Ben H, et al. Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting. Clin Drug Investig. 2015;35(6):365–374.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.